Cepheid Reports 19 Percent Uptick in Q2 Revenues; Battles 'Hangover' Effect from Manufacturing Woes | GenomeWeb

Cepheid last week reported a 19 percent spike in second-quarter revenues, and said that every one of its Xpert molecular diagnostic tests except influenza demonstrated sequential and year-over-year growth in the quarter.

In addition, executives said they were confident that the manufacturing snafu that plagued the company in the latter half of 2012 has been addressed, although the problem caused a "hangover effect" that negatively impacted Q2 commercial operations and will continue to impact bottom-line performance for the rest of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.